Paladin to buy troubled Labopharm for $20M; Abbott gets FDA approval for Lupron doses;

@FiercePharma: Crain's NY predicts Forest Labs will prevail in today's shareholder vote, but Icahn isn't known for giving up easily. Story | Follow @FiercePharma

> Paladin has agreed to buy Labopharm, a Canadian company specializing in controlled release drugs, for about $20.4 million in an effort to strengthen its pain franchise. News | Report

> Abbott Laboratories got the FDA nod for two longer-acting doses of its drug Lupron for use in treating premature puberty. Story

> The Generic Pharmaceutical Association spent about $508,000 on lobbying during the second quarter, focusing primarily on patent issues and healthcare reform provisions covering biosimilar drugs. Item

> Continuing its share-buyback program, AstraZeneca purchased 750,000-plus shares at a price of 2845 pence per share. Article

> Shortages of some hospital drugs have grown so extreme that gray-market scalpers are hawking supplies at exorbitant prices. Story

> Moody's Investors Service hiked its outlook on Biogen Idec to "positive" from "stable" and affirmed its Baa3 rating on $1.1 billion in debt. News

> Hospira shares rose after a Citi Investment Research analyst upgraded them to "hold" from "sell." Piece

Biotech News

@FierceBiotech: Zogenix plots marketing app as pain drug clears PhIII. More | Follow @FierceBiotech

@JohnCFierce: WSJ article on online "dating service" approach to matching approved drugs to new uses. Piece | Follow @JohnCFierce

@RyanMFierce: Far out. Boston Herald reports budding prospects of a Mass. biotech that has sequenced the cannabis genome. Item | Follow @RyanMFierce

@MaureenFierce: Only half of doctors surveyed were aware Brilinta was approved. Most won't switch patients from Plavix. #sermosurveys. Report | Follow @MaureenFierce

> Amarin shares slide as investors fret over fate of AMR101 patent. More

> Stanford investigators match old drugs with new medical uses. Story

> Gentium tanks after it yanks drug apps on FDA data concerns. Report

Manufacturing News

> Turkeys drive Congress to antibiotic action. News

> FDA aims for quality through regulatory science. Story

> The other dark side of Merck's 13,000 layoffs. More

> Recalls expert: Keep a close eye on regulators. Article

> New cause found in most recent Tylenol recall. Details

Vaccine News

> Carbohydrate key to C. diff vaccine. Details

> Novel antibodies could lead to AIDS vaccine. More

> USAID, IDRI form malaria vax collaboration. Report

> TapImmune, Mayo Clinic announce PhI breast cancer vaccine trial. News

> Inviragen, U of Texas land $3M grant for chikungunya vaccine. Article

And Finally... Smokers have a higher risk of bladder cancer than previously believed, perhaps because of new chemicals in cigarettes. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.